Citius Pharmaceuticals to Present at the H.C. Wainwright Global Investment Conference on May 24, 2022

    Author microcapwatchPosted on Categories BiotechTags , , , , , , , , , , , , , ,

    <br /> Citius Pharmaceuticals to Present at the H.C. Wainwright Global Investment Conference on May 24, 2022<br />

    PR Newswire



    CRANFORD, N.J.


    ,


    May 18, 2022


    /PRNewswire/ — Citius Pharmaceuticals, Inc. (“Citius” or the “Company”) (Nasdaq: CTXR), a late-stage biopharmaceutical company developing and commercializing first-in-class critical care products, today announced that it will present at the H.C. Wainwright Global Investment Conference being held

    May 23-26, 2022

    .

    Leonard Mazur

    , Chairman and CEO of Citius, will discuss the Company’s recent business developments and upcoming milestones.



    H.C. Wainwright Global Investor Conference


    Presentation date and time:


    Tuesday, May 24, 2022 at 11:00 a.m. ET


    Location:


    Virtual and at the Fontainebleau Miami Beach Hotel, Miami Beach, Florida


    Registration:


    Visit the

    conference website

    for in-person or virtual registration


    Live webcast:


    Register

    here

    to view


    Webcast replay:


    Available for 90 days

    Interested parties may schedule 1-on-1 meetings with Citius management by registering through the event platform or contacting the Company’s investor relations team.


    About Citius Pharmaceuticals, Inc.

    Citius is a late-stage biopharmaceutical company dedicated to the development and commercialization of first-in-class critical care products, with a focus on oncology, anti-infectives in adjunct cancer care, unique prescription products, and stem cell therapies. The Company has two late-stage product candidates, Mino-Lok

    ®

    , an antibiotic lock solution for the treatment of patients with catheter-related bloodstream infections (CRBSIs), which is currently enrolling patients in a Phase 3 Pivotal superiority trial, and I/ONTAK (E7777), a novel IL-2R immunotherapy for an initial indication in cutaneous T-cell lymphoma (CTCL), which has completed enrollment in its Pivotal Phase 3 trial.  Mino-Lok

    ®

    was granted Fast Track designation by the U.S. Food and Drug Administration (FDA). I/ONTAK has received orphan drug designation by the FDA for the treatment of CTCL and peripheral T-cell lymphoma (PTCL). Through its subsidiary, NoveCite, Inc., Citius is developing a novel proprietary mesenchymal stem cell treatment derived from induced pluripotent stem cells (iPSCs) for acute respiratory conditions, with a near-term focus on acute respiratory distress syndrome (ARDS) associated with COVID-19.  For more information, please visit

    www.citiuspharma.com

    .


    Investor Relations for Citius Pharmaceuticals:



    Ilanit Allen


    Vice President, Investor Relations and Corporate Communications

    T: 908-967-6677 x113

    E:

    [email protected]

    Cision
    View original content to download multimedia:

    https://www.prnewswire.com/news-releases/citius-pharmaceuticals-to-present-at-the-hc-wainwright-global-investment-conference-on-may-24-2022-301549451.html

    SOURCE Citius Pharmaceuticals, Inc.

    PR Newswire
    May 18, 2022 – 6:30 AM PDT